International Journal of Technology Assessment in Health Care

Papers
(The H4-Index of International Journal of Technology Assessment in Health Care is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
OP123 The Use Of Surrogate Outcomes In National Institute For Health And Care Excellence (NICE) Highly Specialised Technology Evaluations: A Review Of Published Guidance158
OP312 Developing A Tool-kit For Assessment Of Autism Spectrum Disorder27
PP94 Pandemic Preparedness: EUnetHTA COVID-19 Rapid Response With “Rolling Collaborative Reviews (RCR)”21
PP114 The Influence Of Implicit Factors On The Health Technology Assessment Deliberative Process: A Survey In Five European Countries18
PP150 The Role Of Expert Consensus In UK Guidance: Patient Selection For Hydrogel Spacer Use During Prostate Cancer Radiotherapy16
PP97 Recommendations For Generating South African Health-Related Quality Of Life Data For Cost-Utility Analyses16
PP53 Applying The VALIDATE Approach To Frame The Assessment Of Integrated Care Management In Aortic Valve Stenosis16
OP42 Increasing Access To Real-World Data To Move From Health Technology Assessment To Health Technology Management15
PD35 Mortality And Risk Factors Associated With Dialysis Patients With COVID-19 In A Brazilian Supplementary Health Service15
PD09 Comparing Long-term Costs Associated With Intraocular Lens Selection And Nd:YAG Laser Capsulotomy In The UK: A Cost-Consequence Analysis15
PP47 Modelling Non-small Cell Lung Cancer Treatment: Predicted and Observed Impact Of Immunotherapy In The Netherlands14
OP60 Methodological Guidance And Doctrine Of The French National Authority For Health For Economic Evaluation13
OP92 Impact Of Real-World Evidence On Health Technology Assessment And National Guidance For Interventional Procedures: A UK Perspective13
PP23 Lost In Translation? The Differences In The Use Of Real-World Evidence Across Key Markets13
0.065819978713989